178 related articles for article (PubMed ID: 37095438)
21. Osteopontin as a potential biomarker of proliferation and invasiveness for lung cancer.
Zhao B; Sun T; Meng F; Qu A; Li C; Shen H; Jin Y; Li W
J Cancer Res Clin Oncol; 2011 Jul; 137(7):1061-70. PubMed ID: 21207061
[TBL] [Abstract][Full Text] [Related]
22. The impact of osteopontin on prognosis and clinicopathology of colorectal cancer patients: a systematic meta-analysis.
Zhao M; Liang F; Zhang B; Yan W; Zhang J
Sci Rep; 2015 Aug; 5():12713. PubMed ID: 26234583
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer.
Rudland PS; Platt-Higgins A; El-Tanani M; De Silva Rudland S; Barraclough R; Winstanley JH; Howitt R; West CR
Cancer Res; 2002 Jun; 62(12):3417-27. PubMed ID: 12067984
[TBL] [Abstract][Full Text] [Related]
24. Overexpressed ostepontin-c as a potential biomarker for esophageal squamous cell carcinoma.
Zhang MX; Xu YJ; Zhu MC; Yan F
Asian Pac J Cancer Prev; 2013; 14(12):7315-9. PubMed ID: 24460294
[TBL] [Abstract][Full Text] [Related]
25. Osteopontin-a splice variant is overexpressed in papillary thyroid carcinoma and modulates invasive behavior.
Ferreira LB; Tavares C; Pestana A; Pereira CL; Eloy C; Pinto MT; Castro P; Batista R; Rios E; Sobrinho-Simões M; Gimba ER; Soares P
Oncotarget; 2016 Aug; 7(32):52003-52016. PubMed ID: 27409830
[TBL] [Abstract][Full Text] [Related]
26. Association of osteopontin expression with the prognosis of glioma patient: a meta-analysis.
Zhao M; Xu H; Liang F; He J; Zhang J
Tumour Biol; 2015 Jan; 36(1):429-36. PubMed ID: 25266800
[TBL] [Abstract][Full Text] [Related]
27. Osteopontin is a prognostic biomarker in non-small cell lung cancer.
Rud AK; Boye K; Oijordsbakken M; Lund-Iversen M; Halvorsen AR; Solberg SK; Berge G; Helland A; Brustugun OT; Mælandsmo GM
BMC Cancer; 2013 Nov; 13():540. PubMed ID: 24215488
[TBL] [Abstract][Full Text] [Related]
28. Osteopontin is a novel prognostic biomarker in early-stage non-small cell lung cancer after surgical resection.
Yan CH; Lv M; Li H; Song X; Yan F; Cao S; Ren X
J Cancer Res Clin Oncol; 2015 Aug; 141(8):1371-8. PubMed ID: 25555465
[TBL] [Abstract][Full Text] [Related]
29. Osteopontin splice variants and polymorphisms in cancer progression and prognosis.
Briones-Orta MA; Avendaño-Vázquez SE; Aparicio-Bautista DI; Coombes JD; Weber GF; Syn WK
Biochim Biophys Acta Rev Cancer; 2017 Aug; 1868(1):93-108.A. PubMed ID: 28254527
[TBL] [Abstract][Full Text] [Related]
30. Wnt-β-catenin-Tcf-4 signalling-modulated invasiveness is dependent on osteopontin expression in breast cancer.
Ravindranath A; Yuen HF; Chan KK; Grills C; Fennell DA; Lappin TR; El-Tanani M
Br J Cancer; 2011 Aug; 105(4):542-51. PubMed ID: 21772333
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of osteopontin expression in gastric cancer: a meta-analysis.
Gu X; Gao XS; Ma M; Qin S; Qi X; Li X; Sun S; Yu H; Wang W; Zhou D
Oncotarget; 2016 Oct; 7(43):69666-69673. PubMed ID: 27626167
[TBL] [Abstract][Full Text] [Related]
32. Assessing SPP1/Osteopontin (OPN) Splice Variants and Their Association to Nonmelanoma Skin Cancer by Absolute Quantification: Identification of OPN-5 Subvariants and Their Protein Coding Potential.
Chou CF; Huang CC; Bin Dabil N; Chang PL
Cancer Invest; 2021; 39(6-7):559-570. PubMed ID: 34043476
[TBL] [Abstract][Full Text] [Related]
33. Osteopontin: its potential role in cancer of children and young adults.
Karpinsky G; Fatyga A; Krawczyk MA; Chamera M; Sande N; Szmyd D; Izycka-Swieszewska E; Bien E
Biomark Med; 2017 Apr; 11(4):389-402. PubMed ID: 28326824
[TBL] [Abstract][Full Text] [Related]
34. An osteopontin splice variant induces anchorage independence in human breast cancer cells.
He B; Mirza M; Weber GF
Oncogene; 2006 Apr; 25(15):2192-202. PubMed ID: 16288209
[TBL] [Abstract][Full Text] [Related]
35. Association of increased osteopontin and splice variant-c mRNA expression with HER2 and triple-negative/basal-like breast carcinomas subtypes and recurrence.
Ortiz-Martínez F; Perez-Balaguer A; Ciprián D; Andrés L; Ponce J; Adrover E; Sánchez-Payá J; Aranda FI; Lerma E; Peiró G
Hum Pathol; 2014 Mar; 45(3):504-12. PubMed ID: 24440093
[TBL] [Abstract][Full Text] [Related]
36. Osteopontin-a alters glucose homeostasis in anchorage-independent breast cancer cells.
Shi Z; Mirza M; Wang B; Kennedy MA; Weber GF
Cancer Lett; 2014 Mar; 344(1):47-53. PubMed ID: 24157812
[TBL] [Abstract][Full Text] [Related]
37. Osteopontin-4 and Osteopontin-5 splice variants are expressed in several tumor cell lines.
Silva GR; Mattos DS; Bastos ACF; Viana BPPB; Brum MCM; Ferreira LB; Gimba ERP
Mol Biol Rep; 2020 Oct; 47(10):8339-8345. PubMed ID: 33006711
[TBL] [Abstract][Full Text] [Related]
38. Osteopontin expression is associated with improved survival in patients with pancreatic adenocarcinoma.
Collins AL; Rock J; Malhotra L; Frankel WL; Bloomston M
Ann Surg Oncol; 2012 Aug; 19(8):2673-8. PubMed ID: 22461132
[TBL] [Abstract][Full Text] [Related]
39. Osteopontin increases hepatocellular carcinoma cell growth in a CD44 dependant manner.
Phillips RJ; Helbig KJ; Van der Hoek KH; Seth D; Beard MR
World J Gastroenterol; 2012 Jul; 18(26):3389-99. PubMed ID: 22807608
[TBL] [Abstract][Full Text] [Related]
40. Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers.
Cao DX; Li ZJ; Jiang XO; Lum YL; Khin E; Lee NP; Wu GH; Luk JM
World J Gastroenterol; 2012 Aug; 18(30):3923-30. PubMed ID: 22912540
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
